Abstract P1-07-33: Impact of family history of breast and/or ovarian cancer in triple negative breast cancer

Abstract

Abstract Background: A family history of breast and/or ovarian cancer (FHBOC) is a risk factor for breast cancer. The influence of FHBOC in the prognosis of triple-negative breast cancer (TNBC) is controversial. The aim of this study was to analyze the impact of FHBOC on the prognosis in TNBC patients. Methods: We retrospectively reviewed a database of patients diagnosed of TNBC (period 2000-2014) and treated at “Instituto Nacional de Enfermedades Neoplasicas”. The patients were divided into two groups: with FHBOC and non-FHBOC. The clinical features and prognosis between groups were compared. Disease-free survival (DFS) and overall survival (OS) differences were calculated by the Kaplan-Meier Method and differences were evaluated by the Log- Rank test. Prognostic factors were identified by the Cox regression analysis. Results: Overall, 266 out of 2007 TNBC patients, had +FHBOC (13.3%). The median age for the general population was 49 years. Compared with the non-FHBOC group (51.1%), the 43.8% +FHBOC were premenopausal. Prevalence of +FHBOC in a first-, second- and a third-degree relative was 26.8%, 28.5%, and 44.7%, respectively. Regarding histological subtype, invasive ductal carcinoma was the most prevalent (93.5%). Clinical stages (CS) II/III was more frequent in both groups (86.3 vs. 86.1). A total of 59% of FHBOC patients underwent surgery and 52% for non-FHBOC (p=0.029- Conservative 41.1 vs. 30.7 - Mastectomy 58.9 vs. 69.3). The median of follow-up was 9 years. DFS rate was higher in FHBOC patients (53.6% vs. 42.9%, p=0.001). OS was significantly better In the FHBOC group (Table 1). In the multivariate analysis, poor prognosis variables to DFS were an advanced age at diagnosis (≥50 years) (p=0.006) and higher clinical stage (CS I vs. CS III, p<0.001) while chemotherapy (CT) and radiotherapy (RT) were associated with an improved DFS. In regard to the OS, FHBOC was associated with a better prognosis (HR:0.77, 95%CI:0.62- 0.95, p=0.016). Conclusion: Our results showed a better prognosis in TNBC patients with family history of breast and/or ovarian cancer in terms of DFS and OS. Table 1. +FHBOC group (DFS/OS rates) +FHBOCnon-FHBOCTotalPDFS (%) 5-years7162630.03210-years635052 OS (%) 5-years665455<0.00110-years584750 Citation Format: Morante Z, De la Cruz-Ku G, Pinto J, Enriquez D, Lujan M, Luque R, Eyzaguirre E, Saavedra A, Fuentes H, Neciosup S, Gomez H. Impact of family history of breast and/or ovarian cancer in triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-33.